Is Compounded Semaglutide Safe?

Compounded semaglutide can be safe — but that safety isn't built into the drug itself, and no one can promise it in the abstract. It depends entirely on the specific pharmacy that prepares it, the ingredient it's made from, and whether a licensed clinician is actually reviewing your case before you're prescribed anything. The more useful question isn't "is compounded semaglutide safe" as a category — it's "is this provider, pharmacy, and product safe," and that's a short, checkable list, not a guess.

The short answer

Compounded semaglutide prepared by a US-licensed compounding pharmacy, prescribed after a real clinician review, can be a reasonable option for the right patient. It is not FDA-approved, is not a generic version of Wegovy® or Ozempic®, and has not been evaluated by the FDA for safety, efficacy, or quality — no legitimate provider will tell you otherwise. The real safety risk isn't the compounding process itself; it's using a provider that skips the pharmacy, the sourcing, or the clinician review that make compounding safe in the first place.

What actually determines whether a compounded GLP-1 is safe?

Three things, and they have nothing to do with the price on the page:

The pharmacy. A legitimate compounded semaglutide prescription is prepared by a US-licensed compounding pharmacy — either a §503A pharmacy compounding against your individual prescription, or a §503B outsourcing facility registered with and inspected by the FDA under current good manufacturing practice. A provider that can't or won't name the pharmacy preparing your medication is a problem, not a detail.
The active ingredient. The FDA has specifically warned about compounded products using unapproved salt forms — semaglutide sodium or semaglutide acetate — that don't match the base form used in the FDA-approved products and haven't been shown to have the same effects. Reputable compounders use semaglutide base.
Clinician oversight. A licensed prescriber needs to actually review your health history and document why a compounded preparation, rather than an FDA-approved one, is appropriate for you — not just approve a payment form.

Get all three right and you're dealing with a legitimate, regulated preparation. Get any one wrong and you're taking on risk that has nothing to do with semaglutide as a molecule.

Is compounded semaglutide FDA-approved?

No. This is worth stating plainly, because it's the one fact every compounded semaglutide provider is required to be upfront about.

Compounded medications are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.

That doesn't mean compounded medications are unregulated — §503A pharmacies are licensed and inspected by state boards of pharmacy and are regulated federally under the FDCA, and §503B outsourcing facilities are additionally registered with and inspected by the FDA. It means the specific compounded preparation you receive has not gone through the FDA's new-drug approval process the way Wegovy® or Ozempic® has, and clinical trial results published for those brand-name products don't transfer to compounded versions.

What are the specific risks the FDA has actually warned about?

The FDA's warnings about compounded GLP-1s are narrower and more specific than "compounding is risky" — they name particular failure modes:

Unapproved salt forms. Semaglutide sodium and semaglutide acetate are not the form used in FDA-approved products, and the FDA has flagged pharmacies compounding with them.
Sourcing from unregistered facilities. Active pharmaceutical ingredient that doesn't come with a valid Certificate of Analysis from an FDA-registered manufacturing site carries no verified chain of custody for identity, purity, or sterility.
Non-compliant compounding. Facilities operating outside §503A or §503B rules — skipping sterility testing, USP compounding standards, or state licensure — are the actual target of FDA enforcement, not compounding pharmacies that follow the rules.
No-prescription sellers. Vials sold without a clinician's review, often labeled "for research use only," aren't pharmaceutical products prepared for human use at all.

None of this means every compounded product is risky — it means the risk concentrates in a specific, identifiable set of shortcuts, all of which are checkable before you pay anyone.

What red flags mean you should walk away?

No prescription required. Semaglutide is a prescription medication everywhere in the US. Any seller willing to ship without a clinician's review is operating illegally, full stop.
"Research use only" labeling. This label signals the product isn't intended, tested, or regulated for human use — not a legal workaround.
The provider won't name its pharmacy. A legitimate telehealth company can tell you exactly which US-licensed pharmacy prepares your medication.
No verifiable certification. Look for LegitScript Healthcare Merchant Certification or an equivalent third-party verification, and actually check it rather than trusting a badge image on a website.
Guaranteed results or specific outcome claims. No legitimate compounded product can cite brand-name clinical trial results as its own — a provider that does is telling you something about how carefully they follow the rules elsewhere, too.

How do you verify a provider before you pay?

Two free, public lookups cover most of it:

LegitScript's certification database. LegitScript maintains a public database of certified healthcare merchants. Search any telehealth provider — including Pallas — before paying, and confirm the certification is current rather than expired or aspirational.
The FDA's BeSafeRx pharmacy locator. BeSafeRx helps confirm a pharmacy is licensed by a state board of pharmacy, requires a valid prescription, provides a real US address and phone number, and has a licensed pharmacist available to answer questions. If a pharmacy isn't listed or won't answer basic licensing questions, that's your answer.

A provider that passes both checks, names its pharmacy, and puts you through an actual health review before prescribing has cleared the bar that separates a legitimate compounded GLP-1 program from the sellers the FDA warns about.

Why would a clinician prescribe compounded instead of Wegovy® or Ozempic®?

Not for price, and not for preference alone. Both the semaglutide shortage (resolved February 21, 2025) and the tirzepatide shortage (resolved December 19, 2024) have ended, which means shortage status no longer justifies a compounded prescription. Under FDCA §503A(b)(1)(C), a licensed prescriber can compound a preparation when they document a patient-specific clinical reason an FDA-approved product isn't appropriate for that individual — for example, an intolerance to an inactive ingredient in the brand-name formulation, or a need for a dose strength that isn't commercially available. A program that hands out compounded prescriptions to everyone regardless of history, with no documented rationale, isn't following that standard.

Wondering if you qualify?

A quick health questionnaire is reviewed by a US-licensed clinician, who determines whether treatment — compounded or brand-name — is appropriate for you. Nothing ships without that review.

Start your intake →

Where Pallas fits

Pallas is LegitScript Healthcare Merchant Certified, and every prescription — compounded or brand-name — starts with a real intake reviewed by a US-licensed clinician. Compounded semaglutide dispensed through Pallas is prepared by US-licensed compounding pharmacies; Pallas also dispenses FDA-approved Wegovy® and Ozempic® on a cash-pay basis when a clinician determines that's the better fit. Both options are cash-pay, and eligibility is always a clinical decision, not a checkout formality. For the fuller comparison of how the two tiers differ, see compounded vs. brand-name GLP-1 medications; for what compounded pricing looks like, see how much compounded semaglutide costs. Coverage and telehealth rules vary slightly by state — check yours in the state-by-state GLP-1 directory, or read more about the full GLP-1 program.

Frequently asked questions

No. Compounded semaglutide is prepared per-patient by a US-licensed compounding pharmacy and is not FDA-approved, is not a generic version of Ozempic^® or Wegovy^®, and has not been evaluated by the FDA for safety, efficacy, or quality. Clinical trial results published for the FDA-approved products have not been established for compounded preparations.

Using a provider that skips the parts that make compounding safe: a named, US-licensed pharmacy; semaglutide base (rather than an unapproved salt form like semaglutide sodium or semaglutide acetate); and a real clinician review before prescribing. The FDA's specific warnings target sellers that skip these steps — not the practice of pharmacy compounding itself, which is legal and regulated.

Two free lookups cover most of it: search the provider in LegitScript's public certification database, and confirm its pharmacy is state-licensed using the FDA's BeSafeRx locator. A legitimate provider can also simply tell you which pharmacy prepares your medication when you ask.

Yes, just differently than FDA-approved drugs. §503A compounding pharmacies are licensed and inspected by state boards of pharmacy and regulated federally under the FDCA; §503B outsourcing facilities are additionally registered with and inspected by the FDA under current good manufacturing practice. What compounded preparations don't have is FDA approval of the specific preparation itself — that's a separate process the compounded product hasn't gone through.

With both the semaglutide and tirzepatide shortages now resolved, compounding requires a documented, patient-specific clinical reason under FDCA §503A(b)(1)(C) — for example, an intolerance to an inactive ingredient in the FDA-approved formulation, or a need for a dose strength that isn't commercially available. Cost or preference alone isn't a sufficient basis. A provider that prescribes compounded medication to everyone regardless of history isn't following that standard.

No. Semaglutide is a prescription medication everywhere in the US. Sites that ship it without a clinician's review — often labeling vials 'for research use only' — are not legitimate pharmacies, are not preparing product for verified human use, and are operating outside the law regardless of how the product is marketed.

References

U.S. Food and Drug Administration. FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss. 2026.
U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. 2026.
U.S. Food and Drug Administration. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs. 2026.
U.S. Food and Drug Administration. Locate a State-Licensed Online Pharmacy (BeSafeRx). 2024.
Gabay M. The Drug Quality and Security Act. Hosp Pharm. 2014;49(7):615–676.

Bottom line: Compounded semaglutide isn't automatically safe or automatically risky — it depends on the pharmacy preparing it, the ingredient it's made from, and whether a real clinician reviewed your case first. It is not FDA-approved, is not a generic version of Wegovy® or Ozempic®, and has not been evaluated by the FDA for safety, efficacy, or quality. Verify any provider's LegitScript certification and its pharmacy's state licensing before you pay, walk away from anyone who skips the prescription, and let a licensed clinician — not a price tag — decide whether compounded or brand-name treatment fits you.

Check your eligibility with a licensed clinician

Complete a short health questionnaire, and a US-licensed clinician will review your history and recommend whether compounded or brand-name treatment is appropriate — no obligation, no membership fee.